Clinical Trials
2
Active:0
Completed:2
Trial Phases
1 Phases
Not Applicable:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Not Applicable
2 (100.0%)Continued Access Study VIG Anastomotic Connector
Not Applicable
Completed
- Conditions
- Dialysis Access Malfunction
- First Posted Date
- 2022-07-08
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Phraxis, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT05448950
- Locations
- 🇺🇸
Trinity Research Group, LLC, Dothan, Alabama, United States
🇺🇸Surgical Specialists of Charlotte, Charlotte, North Carolina, United States
Clinical Evaluation of a Vascular Venous Anastomotic Connector [InterGraft VIG-only Study]
Not Applicable
Completed
- Conditions
- End Stage Renal Disease
- First Posted Date
- 2015-08-26
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- Phraxis, Inc.
- Target Recruit Count
- 158
- Registration Number
- NCT02532621
- Locations
- 🇺🇸
Triad of Alabama/Flowers Hospital, Dothan, Alabama, United States
🇺🇸Cartersville Medical Center, LLC, Cartersville, Georgia, United States
🇺🇸Medical Center of Central Georgia - Navicent Health, Macon, Georgia, United States
News
FDA Approves Phraxis' EndoForce™ Connector, Advancing Hemodialysis Access Technology
Phraxis Inc. has received FDA approval for EndoForce™ Connector, an innovative endovascular implant designed to simplify arteriovenous graft creation for hemodialysis patients.